We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd

Delisted

CYTO was delisted on the 19th of December, 2024.

4 hedge funds and large institutions have $26.7K invested in Altamira Therapeutics Ltd in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.54% more ownership

Funds ownership: 0% → 0.54% (+0.54%)

50% less funds holding

Funds holding: 8 → 4 (-4)

67% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 6

85% less capital inflows, than outflows

Capital inflows: $33.4K | Capital outflows: $217K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-4
Holders Change %
-50%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

CYTO Hedge Fund Activity: Q4 2023 in Review

4 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2023, worth a combined $26.7K — down 88% from $217K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CYTO and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $29.7K. The largest seller was Armistice Capital, exiting entirely with an estimated $203K sold.

  • 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2023, down from 8 in Q3 2023.
  • Funds reported $26.7K of Altamira Therapeutics Ltd stock for Q4 2023, down 88% quarter-over-quarter.
  • 2 funds opened new Altamira Therapeutics Ltd positions in Q4 2023 and 6 closed out, a net change of -4 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q4 2023 was UBS Group, an estimated $29.7K added.
  • The largest Altamira Therapeutics Ltd seller in Q4 2023 was Armistice Capital, an estimated $203K sold.

Based on aggregated 13F filings for Q4 2023.